Amgen and AstraZeneca’s TEZSPIRE approved by FDA for chronic rhinosinusitis with nasal polyps in adults and pediatric patients 12 years and older. It is the first biologic targeting TSLP for this condition, expanding its indication to a second disease driven by epithelial inflammation. CRSwNP affects 320 million people globally, causing persistent inflammation, polyp growths, airflow obstruction, nasal congestion, and reduced sense of smell. Regulatory applications for TEZSPIRE in CRSwNP are under review in Europe, China, Japan, and other countries based on data from the WAYPOINT trial.

Read more at Nasdaq: Amgen And AstraZeneca’s TEZSPIRE Approved For Epithelial-Driven Nasal Inflammation